BioSpace News Archive

Sharps Compliance Corp. reported financial results for the first quarter of fiscal year 2020, ended September 30, 2019.

Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF) (“Aleafia Health” or the “Company”) will announce its 2019 Third Quarter Financial Results on November 12, 2019 prior to market open.

Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced preliminary data from an expanded access study administering investigational AXO-AAV-GM2 gene therapy in two patients with infantile Tay-Sachs disease (TSD) at the 27th Annual Congress of the European Society of Gene and Cell Therapy.

Verastem, Inc. announced that five posters highlighting clinical data for COPIKTRA™ will be presented at the Lymphoma & Myeloma 2019 International Congress taking place October 23-26, 2019, in New York City.

OpGen, Inc. announced that the United States Patent and Trademark Office has allowed a key OpGen patent covering the Lighthouse Profiling technology used in the company’s software for tracking antimicrobial resistant pathogens.

Rigel Pharmaceuticals, Inc. provided a business update that will be discussed in more detail on the company’s investor and analyst call

TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) (“TerrAscend” or “the Company”), the first and only global cannabis company licensed for sales in Canada, the US, and the EU, announced today that it has formed a strategic partnership with Kindred Partners Inc.

Ambrx and NovoCodex Biopharmaceuticals Ltd., (NovoCodex), a majority owned company of Zhejiang Medicine Co Ltd., today announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates (ADCs).

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that Jennifer Chao has been appointed chairperson of its board of directors,

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D., Principal Investigator and Director of R&D, served as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the Company’s Vision Restoration Program at Neuroscience 2019